At Olink Proteomics, Dr. Renu Balyan is the Scientific Liaison for Asia-Pacific. Prior to Olink, she was the Biomarker Lead at Tessa Therapeutics in Singapore and was working on the development of biomarkers for CAR-T cell therapy clinical trials for classical Hodgkin and Non-Hodgkin’s Lymphoma. Her postdoctoral research at the National University of Singapore was on genome-wide CRISPR/Cas9 screening in T cells for discovery of novel immunotherapeutic targets. She received her Doctorate in Immunology from the National Institute of Immunology in India. She has worked extensively on the identification of novel immunotherapeutic targets & drug development, biomarker discovery and development, and precision medicine.